|Bid||244.26 x 1800|
|Ask||244.38 x 1100|
|Day's range||242.21 - 249.96|
|52-week range||214.39 - 296.67|
|Beta (5Y monthly)||0.66|
|PE ratio (TTM)||20.23|
|Forward dividend & yield||8.52 (3.46%)|
|Ex-dividend date||14 Feb 2023|
|1y target est||N/A|
The stock of veteran biotech Amgen (NASDAQ: AMGN) was looking a little tired on Wednesday. The company's shares fell more than 2% in price, "thanks" to fourth-quarter results that didn't put smiles on investors' faces. In contrast to gloomy Amgen, the S&P 500 index ticked up by slightly more than 1%.
Amgen (AMGN) beats Q4 estimates for earnings and sales. It launches Amjevita in the United States, which is the first biosimilar of Humira to be launched in the country.
Amgen Inc. ( NASDAQ:AMGN ) will increase its dividend from last year's comparable payment on the 8th of March to $2.13...